Loading...
•
Jun 30, 2024
ACADIA Q2 2024 Earnings Report
Acadia reported a strong Q2 2024 with significant revenue growth and advancements in clinical trials.
Key Takeaways
Acadia Pharmaceuticals announced a successful second quarter in 2024, marked by a 46% year-over-year increase in total net product sales, driven by growth in both NUPLAZID and DAYBUE sales. The company is also progressing with its Phase 3 trial in Prader-Willi syndrome and Phase 2/Phase 3 program in Alzheimer’s disease psychosis.
Total net product sales reached $242.0 million, a 46% increase year-over-year.
NUPLAZID net sales grew by 11% year-over-year, with a 6% increase in unit sales.
DAYBUE net sales showed an 11% sequential growth.
Acadia is advancing enrollment in Phase 3 trial for Prader-Willi syndrome and Phase 2/Phase 3 program for Alzheimer’s disease psychosis.
ACADIA
ACADIA
ACADIA Revenue by Segment
Revenue by Segment
NUPLAZID Sales Revenue
CapyFin.comDAYBUE Sales Revenue
CapyFin.com Forward Guidance
Acadia is updating its 2024 guidance.
Positive Outlook
- NUPLAZID net product sales guidance is increased to a range of $590 to $610 million from the previous range of $560 to $590 million, reflecting stronger underlying demand driving recent higher unit volume.
- Total revenue guidance is revised to a range of $930 to $980 million from the previous range of $930 million to $1.01 billion.
- R&D expense guidance is narrowed to the lower end of the previous range and is now expected to be between $305 to $315 million.
- SG&A expense guidance is narrowed to the higher end of the previous range and is now expected to be between $465 to $480 million.
Challenges Ahead
- DAYBUE net product sales guidance is decreased to a range of $340 to $370 million from the previous range of $370 to $420 million.
Revenue & Expenses
Visualization of income flow from segment revenue to net income